Elissa A.S. Polomski , Ellen W. Kapiteijn , Julius C. Heemelaar , Anne V. van der Kolk , Timo M. Kalisvaart , Alina van de Burgt , Petra Dibbets-Schneider , Floris H.P. van Velden , Tom T.P. Seijkens , J. Lauran Stöger , J. Wouter Jukema , Lioe-Fee de Geus-Oei , M. Louisa Antoni
{"title":"Arterial inflammation on [18F]FDG PET/CT in melanoma patients treated with and without immune checkpoint inhibitors: CHECK-FLAME I","authors":"Elissa A.S. Polomski , Ellen W. Kapiteijn , Julius C. Heemelaar , Anne V. van der Kolk , Timo M. Kalisvaart , Alina van de Burgt , Petra Dibbets-Schneider , Floris H.P. van Velden , Tom T.P. Seijkens , J. Lauran Stöger , J. Wouter Jukema , Lioe-Fee de Geus-Oei , M. Louisa Antoni","doi":"10.1016/j.atherosclerosis.2024.118595","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and aims</h3><p>Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified. This study aims to assess differences in increase in arterial inflammation between patients with advanced melanoma treated with ICIs compared to a control group without ICIs.</p></div><div><h3>Methods</h3><p>Patients with advanced melanoma who underwent [<sup>18</sup>F]FDG PET/CT scans at baseline, 6 months (T1) and 18 months (T2) were included in this retrospective observational study. Arterial inflammation was evaluated in eight segments by calculating the target-to-background ratio (TBR). The primary study outcome was the difference in increase in mean TBR<sub>max</sub> between patients treated with and without ICIs.</p></div><div><h3>Results</h3><p>We included 132 patients of whom 72.7 % were treated with ICIs. After exclusion for the use of anti-inflammatory medication, patients treated with ICIs showed a significant increase in mean TBR<sub>max</sub> between baseline and T1 from 1.29 ± 0.12 to 1.33 ± 0.13 (<em>p =</em> 0.017), while in the control group, no change in mean TBR<sub>max</sub> (1.30 ± 0.12 to 1.28 ± 0.10, <em>p =</em> 0.22) was observed (<em>p =</em> 0.027). During longer follow-up, mean TBR<sub>max</sub> remained stable in both groups. Arterial inflammation increased significantly after ICI therapy in patients without active inflammation (<em>p</em> < 0.001) and in patients without calcifications (<em>p =</em> 0.013).</p></div><div><h3>Conclusions</h3><p>A significant increase in arterial inflammation as measured on [<sup>18</sup>F]FDG PET/CT was observed in patients with advanced melanoma treated with ICIs only in the first six months after initiation of therapy, whereas no changes were observed in the control group. Moreover, arterial inflammation was mainly increased in patients without pre-existing inflammatory activity and with non-calcified lesions.</p></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":null,"pages":null},"PeriodicalIF":4.9000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0021915024011675/pdfft?md5=21ad258d1059bd9674acf07956182932&pid=1-s2.0-S0021915024011675-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Atherosclerosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0021915024011675","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background and aims
Immune checkpoint inhibitors (ICIs) revolutionized cancer treatment. However, ICIs may increase the immune response to non-tumor cells, possibly resulting in increased arterial inflammation, raising the risk of atherosclerotic events. Nevertheless, malignancies may induce a pro-inflammatory state and the association between ICIs and arterial inflammation remains to be clarified. This study aims to assess differences in increase in arterial inflammation between patients with advanced melanoma treated with ICIs compared to a control group without ICIs.
Methods
Patients with advanced melanoma who underwent [18F]FDG PET/CT scans at baseline, 6 months (T1) and 18 months (T2) were included in this retrospective observational study. Arterial inflammation was evaluated in eight segments by calculating the target-to-background ratio (TBR). The primary study outcome was the difference in increase in mean TBRmax between patients treated with and without ICIs.
Results
We included 132 patients of whom 72.7 % were treated with ICIs. After exclusion for the use of anti-inflammatory medication, patients treated with ICIs showed a significant increase in mean TBRmax between baseline and T1 from 1.29 ± 0.12 to 1.33 ± 0.13 (p = 0.017), while in the control group, no change in mean TBRmax (1.30 ± 0.12 to 1.28 ± 0.10, p = 0.22) was observed (p = 0.027). During longer follow-up, mean TBRmax remained stable in both groups. Arterial inflammation increased significantly after ICI therapy in patients without active inflammation (p < 0.001) and in patients without calcifications (p = 0.013).
Conclusions
A significant increase in arterial inflammation as measured on [18F]FDG PET/CT was observed in patients with advanced melanoma treated with ICIs only in the first six months after initiation of therapy, whereas no changes were observed in the control group. Moreover, arterial inflammation was mainly increased in patients without pre-existing inflammatory activity and with non-calcified lesions.
期刊介绍:
Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.
Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.